MDI 1228
Alternative Names: MDI-1228Latest Information Update: 26 Jul 2024
At a glance
- Originator Shanghai Medinno Pharmaceutical Technology
- Class Antiallergics
- Mechanism of Action Janus kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Allergic conjunctivitis
Most Recent Events
- 30 May 2024 Shanghai Medinno Pharmaceutical Technology completes a phase I trial in Allergic conjunctivitis (In volunteers) in Australia (Ophthalmic) (NCT05969236)
- 01 Aug 2023 Phase-I clinical trials in Allergic conjunctivitis (In volunteers) in Australia (Ophthalmic) (NCT05969236)